 |
|
|
| |
Lp(a) in people living with HIV
|
| |
| |
AIDS 2022 July 29-Aug 1 Montreal
I think HIV clinicians ad HIV cardiologists are not adequately considering this test Lp(a) in their patient evaluations for risk for heart disease. Jules
S. Noe * (1), S. Heldwein (1), F. Schabaz (1), A. von Krosigk (1), C. Wiese (1), E. Julia (1), A. Balogh (2), E. Wolf (2), C. Jonsson-Oldenbuettel (1), ArcHIV Study Group
Institutions
(1) MVZ Munchen am Goetheplatz, Munich, Germany, (2) MUC Research, Munich, Germany
Background
Cardiovascular morbidity and mortality have become major concerns in the medical care of people living with HIV. While a lot of traditional and even HIV-specific risk factors are implemented in frequently used scores for cardiovascular risk assessment, the contribution of Lp(a) in people living with HIV is often under-recognized. This study aimed to describe findings on Lp(a) in a sample of people living with HIV.
Methods
Retrospective analysis from electronic patient files from the ongoing Munich ArcHIV cohort. All people living with HIV with available routine data on Lp(a) from the first quarter of 2021 were included into the analysis. Cardiovascular risk was assessed using the Framingham score to estimate the probability for a major cardiovascular event within the next 10 years (high risk: >20%; low- or intermediate risk <20%). Lp(a) concentrations >30 md/dL were considered to be elevated. Medians with interquartile ranges and absolute numbers and percentages were used for continuous and categorical variables, respectively.
|
| |
|
|
|
|
|
